Kevin Mcculloch Sells 15,000 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin Mcculloch sold 15,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $8.02, for a total transaction of $120,300.00. Following the transaction, the insider owned 1,676,126 shares in the company, valued at $13,442,530.52. The trade was a 0.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Wednesday, July 1st, Kevin Mcculloch sold 90,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.03, for a total transaction of $722,700.00.

Xeris Biopharma Stock Down 1.0%

Shares of NASDAQ:XERS opened at $8.11 on Thursday. The firm has a market capitalization of $1.40 billion, a PE ratio of 135.17 and a beta of 0.66. The business has a 50 day simple moving average of $7.62 and a two-hundred day simple moving average of $6.79. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The firm had revenue of $83.13 million for the quarter, compared to the consensus estimate of $79.83 million. On average, equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Institutional Trading of Xeris Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Kestra Advisory Services LLC purchased a new position in Xeris Biopharma during the 4th quarter worth $25,000. KBC Group NV purchased a new stake in Xeris Biopharma in the first quarter valued at about $27,000. Caitong International Asset Management Co. Ltd raised its stake in Xeris Biopharma by 9,276.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after buying an additional 7,421 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Xeris Biopharma by 179.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after acquiring an additional 1,820 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.